135 related articles for article (PubMed ID: 1763504)
1. The influence of cryopreservation on activity and surface markers of lymphokine-activated killer cells.
Letellier C; Rameliarison L; Fizet D; Ferrer AM; Vezon G
Vox Sang; 1991; 61(2):90-5. PubMed ID: 1763504
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of cryopreservation on natural killer cell and lymphokine-activated killer cell activities.
Martí F; Miralles A; Peiró M; Amill B; de Dalmases C; Piñol G; Rueda F; García J
Transfusion; 1993 Aug; 33(8):651-5. PubMed ID: 8342231
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
4. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
5. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
[TBL] [Abstract][Full Text] [Related]
6. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
7. Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes.
Kawai H; Komiyama A; Katoh M; Yabuhara A; Miyagawa Y; Akabane T
Transfusion; 1988; 28(6):531-5. PubMed ID: 3264091
[TBL] [Abstract][Full Text] [Related]
8. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
Yoneda K; Yamamoto T; Ueta E; Osaki T
J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
10. Swainsonine, a glycosylation inhibitor, enhances both lymphocyte efficacy and tumour susceptibility in LAK and NK cytotoxicity.
Galustian C; Foulds S; Dye JF; Guillou PJ
Immunopharmacology; 1994; 27(2):165-72. PubMed ID: 7516929
[TBL] [Abstract][Full Text] [Related]
11. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cell activity after cryopreservation.
Schmidt-Wolf IG; Aihara M; Negrin RS; Blume KG; Chao NJ
J Immunol Methods; 1989 Dec; 125(1-2):185-9. PubMed ID: 2607152
[TBL] [Abstract][Full Text] [Related]
15. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
16. IL-6 enhances the cytotoxic activity of thymocyte-derived CD56+ cells.
Iho S; Shau H; Golub SH
Cell Immunol; 1992 Oct; 144(1):1-10. PubMed ID: 1382861
[TBL] [Abstract][Full Text] [Related]
17. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
18. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; Rodríguez-Fernández JM
Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
